ERBB2 and neoplasm: This proof-of-concept study demonstrated that GDC-0810 was safe and generally well tolerated with predictable pharmacokinetics, evidence of robust target engagement, and encouraging anti-tumor activity in heavily pretreated patients with advanced or metastatic ER + (HER2 −) breast cancer.